PMID- 22122879
OWN - NLM
STAT- MEDLINE
DCOM- 20120508
LR  - 20120109
IS  - 1878-4216 (Electronic)
IS  - 0278-5846 (Linking)
VI  - 36
IP  - 2
DP  - 2012 Mar 30
TI  - Increased serum Dickkopf-1 levels in drug-abusing psychotic patients.
PG  - 239-44
LID - 10.1016/j.pnpbp.2011.11.006 [doi]
AB  - BACKGROUND: Dickkopf-1 (DKK1) is an inhibitor of the canonical Wnt pathway, which 
      is known to be impaired in both psychotic and neurodegenerative disorders. Here, 
      we examined serum DKK1 levels as an indicator of ongoing neurodegeneration in 
      psychotic patients, with or without a recent or current history of drug abuse. 
      METHODS: We measured serum DKK1 levels by ELISA in 22 inpatients with psychosis 
      and no history of drug abuse, 22 with psychosis and drug abuse, and 16 controls. 
      We rated psychopathology using the following rating scales: the Positive and 
      Negative Syndrome Scale (PANSS); the Clinical Global Impressions (CGI) severity 
      scale; and the Global Assessment of Functioning (GAF) scale. Extrapyramidal motor 
      symptoms were assessed by the Simpson-Angus Neurological Rating Scale (NRS). 
      RESULTS: Inpatients with psychosis and comorbid substance abuse showed 
      significantly higher serum DKK1 levels than inpatients with psychosis and no 
      comorbid substance abuse or controls. Comorbid patients had earlier onset, longer 
      duration of psychosis, and more severe extrapyramidal motor symptoms. However, we 
      did not find any significant correlation between DKK1 levels and rating scale 
      scores. CONCLUSION: Psychosis led to elevated serum DKK1 levels, and substance 
      abuse led to a further increase. Knowing that there is a correlation between 
      brain and blood levels of DKK1, we speculate that the observed increase in DKK1 
      levels reflects drug-induced neurotoxicity in our patients.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Serata, Daniele
AU  - Serata D
AD  - NESMOS Department (Neurosciences, Mental Health and Sensory Organs), School of 
      Medicine and Psychology, Sapienza University-Rome, Sant'Andrea Hospital, Rome, 
      Italy. seratadaniele@gmail.com
FAU - Kotzalidis, Giorgio D
AU  - Kotzalidis GD
FAU - Riozzi, Barbara
AU  - Riozzi B
FAU - Storto, Marianna
AU  - Storto M
FAU - Panaccione, Isabella
AU  - Panaccione I
FAU - Romano, Silvia
AU  - Romano S
FAU - Rapinesi, Chiara
AU  - Rapinesi C
FAU - Porfiri, Giulio Maria
AU  - Porfiri GM
FAU - Casolla, Barbara
AU  - Casolla B
FAU - Del Casale, Antonio
AU  - Del Casale A
FAU - Curto, Martina
AU  - Curto M
FAU - Caloro, Matteo
AU  - Caloro M
FAU - Girardi, Nicoletta
AU  - Girardi N
FAU - Savoja, Valeria
AU  - Savoja V
FAU - Nicoletti, Ferdinando
AU  - Nicoletti F
FAU - Tatarelli, Roberto
AU  - Tatarelli R
FAU - Girardi, Paolo
AU  - Girardi P
LA  - eng
PT  - Journal Article
DEP - 20111121
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (DKK1 protein, human)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
SB  - IM
MH  - Adult
MH  - Basal Ganglia Diseases/blood/complications
MH  - Case-Control Studies
MH  - Diagnosis, Dual (Psychiatry)
MH  - Female
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/*blood
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales/statistics & numerical data
MH  - Psychotic Disorders/*blood/complications
MH  - Substance-Related Disorders/*blood/complications
EDAT- 2011/11/30 06:00
MHDA- 2012/05/09 06:00
CRDT- 2011/11/30 06:00
PHST- 2011/07/13 00:00 [received]
PHST- 2011/11/14 00:00 [revised]
PHST- 2011/11/14 00:00 [accepted]
PHST- 2011/11/30 06:00 [entrez]
PHST- 2011/11/30 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
AID - S0278-5846(11)00335-6 [pii]
AID - 10.1016/j.pnpbp.2011.11.006 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):239-44. doi: 
      10.1016/j.pnpbp.2011.11.006. Epub 2011 Nov 21.